Plasma-Derived Therapies – Critical Treatments Demand Global Commitment Ramy Riad, Chief Financial Officer, Plasma-Derived Therapies Business Unit, Takeda | March 22, 2026

https://www.healthaffairs.org/sponsored-content/plasma-derived-therapies-critical-treatments-demand-global-commitment?utm_campaign=34032557-Health%20Affairs%20Sunday%20Update%202026&utm_medium=email&_hsenc=p2ANqtz-9FxtWavPjcpEw_3AppkZ42sBoi3UElXYSaNpZ9sVulufDH6DStfwX0rZ3bgAIydVFPJeUMH3nYh99lyi5D8VGzPobeQw&_hsmi=409799600&utm_content=409799600&utm_source=hs_email Plasma: A Critical Lifeline Under Pressure For millions of patients worldwide, many living with rare and chronic illnesses, plasma-derived therapies (PDTs) are essential. They improve and help sustain health and quality of life across a wide range of conditions, from bleeding disorders to immunodeficiencies – and for many patients there is no alternative.